ECM
PRME icon

ExodusPoint Capital Management’s Prime Medicine PRME Stock Holding History

ExodusPoint Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-33,494
Closed -$186K – 1958
2025
Q3 		$186K Buy
+33,494
New +$136K ﹤0.01% 1396
2025
Q1 		– Sell
-131,732
Closed -$385K – 1892
2024
Q4 		$385K Buy
+131,732
New +$462K ﹤0.01% 1218

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

ExodusPoint Capital Management's PRME Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 33,494 shares — an estimated $186K sold.

ExodusPoint Capital Management first reported a position in PRME in Q4 2024 and held it in 2 quarters. The position peaked at $385K in Q4 2024. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 33,494 Prime Medicine shares in Q4 2025, an estimated $186K.
  • ExodusPoint Capital Management first reported a position in Prime Medicine in Q4 2024 and held it in 2 quarters.
  • ExodusPoint Capital Management's Prime Medicine position peaked at $385K in Q4 2024.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.